WASHINGTON - Drug companies that have fought against easy approvals for follow-on protein products aren't letting up these days, but their generic counterparts may be gaining some footholds as they clearly have their sights set on the lucrative and growing biopharmaceutical market. (BioWorld Today) Read More
